Trials / Completed
CompletedNCT00732992
A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies
Phase 1 Study Of Sunitinib (SU011248) In Combination With Pemetrexed In Patients With Advanced Solid Malignancies In Japan
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess if the combination of sunitinib and pemetrexed is tolerable when coadministered at each recommended dose/schedule.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib, Pemetrexed | Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity. |
| DRUG | Sunitinib, Pemetrexed | Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity. |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2008-08-12
- Last updated
- 2011-03-17
- Results posted
- 2010-11-25
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00732992. Inclusion in this directory is not an endorsement.